Exact Sciences Corporation

444 articles with Exact Sciences Corporation

• Exact Sciences to participate in June 2021 investor conferences

  5/24/2021

  Exact Sciences Corp. announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.

• Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

  5/19/2021

  Exact Sciences Corp., a global leader in cancer diagnostics, announced new data on its cancer tests and treatment guidance tools will be showcased in seven presentations and one e-abstract at the 2021 American Society of Clinical Oncology Annual Meeting, being held virtually June 4-8.

• Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45

  5/19/2021

  The United States Preventive Services Task Force released its final colorectal cancer screening recommendation that screening begin at age 45.

• Promega, Exact Sciences Partnering to Help Jumpstart Colorectal Cancer Screenings

  5/10/2021

  Serious runners and casual walkers alike are invited to join a month-long Get Your Rear in Gear® - Madison run/walk virtual event during May to raise money and awareness for colorectal cancer screening efforts.

• Exact Sciences Announces First Quarter 2021 Results

  5/4/2021

  Exact Sciences Corp. announced that the company generated revenue of $402.1 million for the first quarter ended March 31, 2021, compared to $347.8 million for the same period of 2020.

• Exact Sciences to participate in May 2021 investor conferences

  5/3/2021

  Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.

• Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People

  4/28/2021

  Exact Sciences announces study results published in Mayo Clinic Proceedings showing that Cologuard is the most cost-effective colorectal cancer screening option in the Alaska Native population, as compared to colonoscopy and the fecal immunochemical test, for a wide range of adherence scenarios.

• Exact Sciences Completes Acquisition of Ashion Analytics, LLC, from The Translational Genomics Research Institute, an affiliate of City of Hope

  4/14/2021

  Talented team and industry-leading lab will help strengthen the company's sequencing and pipeline capabilities, while broadening its therapy selection and treatment guidance offerings

• Exact Sciences schedules first quarter 2021 earnings call

  4/8/2021

  Exact Sciences Corp. announced that the company plans to release its first quarter 2021 financial results after the close of the U.S. financial markets on May 4, 2021.

• Exact Sciences to participate in March 2021 investor conferences

  2/22/2021

  Exact Sciences Corp. announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.

• Exact Sciences Announces Fourth Quarter 2020 Results

  2/16/2021

  Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466 .3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020 .

• Exact Sciences to participate in February 2021 investor conferences

  2/1/2021

  Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.

• Exact Sciences schedules fourth quarter 2020 earnings call

  2/1/2021

  Exact Sciences Corp. announced that the company plans to release its fourth quarter 2020 financial results after the close of the U.S. financial markets on February 16, 2021.

• Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology

  1/13/2021

  Worldwide Exclusive License Provides Access to Targeted Digital Sequencing (TARDIS) Blood Biopsy Method for Use in Minimal Residual Disease Testing

• New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®

  1/12/2021

  Cologuard's high specificity would help minimize risk and cost from unnecessary diagnostic procedures in this age group

• Exact Sciences Announces Preliminary Fourth Quarter 2020 Results

  1/11/2021

  Expected total revenue of $464.5-467.5M, including Screening revenue of $249-250M, Precision Oncology revenue of $117-118M, and COVID-19 testing revenue of $98.5-99.5M

• Exact Sciences to participate in J.P. Morgan Healthcare Conference - Dec 28, 2020

  12/28/2020

  Exact Sciences Corp. announced that company management will participate in the following conference and invited investors to participate by webcast.

• Exact Sciences to participate in December 2020 investor conference

  11/23/2020

  Exact Sciences Corp. announced that company management will participate in the following conference and invited investors to participate by webcast.

• Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)

  11/17/2020

  Consortium aims to make comprehensive genomic profiling accessible to advanced cancer patients in the U.S. to inform medical management and improve patient outcomes.

• Exact Sciences to participate in November 2020 investor conferences

  11/2/2020

  Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.